Krystal Biotech beats Q3 earnings, but trial delays send shares lower. Analysts call the market drop overblown and highlight a potential buying opportunity.read more...
Krystal Biotech beats Q3 earnings, but trial delays send shares lower. Analysts call the market drop overblown and highlight a potential buying opportunity.read more...
Krystal Biotech (KRYS) delivered earnings and revenue surprises of +11.41% and +2.16%, respectively, for the quarter ended September 2026. Do the numbers hold clues to what lies ahead for the stock?
Krystal Biotech (NASDAQ:KRYS) reported third-quarter financial results on Monday. The transcript from the company's third-quarter earnings call has been provided below.This transcript is brought to you by Benzinga APIs.read more...
Amgen (AMGN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Krystal Biotech (KRYS) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Krystal Biotech (NASDAQ:KRYS) has outperformed the market over the past 5 years by 31.65% on an annualized basis producing an average annual return of 42.52%. Currently, Krystal Biotech has a market capitalization ofread more...
Krystal Biotech reports promising early results for KB113, with tumor regression seen in more than 80% of assessed lesions in an early Gorlin syndrome study.
Krystal Biotech (NASDAQ:KRYS) has outperformed the market over the past 5 years by 32.16% on an annualized basis producing an average annual return of 44.36%. Currently, Krystal Biotech has a market capitalization ofread more...
Krystal Biotech (NASDAQ:KRYS) has outperformed the market over the past 5 years by 32.48% on an annualized basis producing an average annual return of 43.76%. Currently, Krystal Biotech has a market capitalization ofread more...